Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24594934.
- Also identified by DOI 10.1126/science.1248707 and PMC identifier 4308974.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GSK1265744 (GSK744) is an integrase strand-transfer inhibitor that has been formulated as a long-acting (LA) injectable suitable for monthly to quarterly clinical administration. GSK744 LA was administered at two time points 4 weeks apart beginning 1 week before virus administration, and macaques were challenged weekly for 8 weeks. GSK744 LA, at plasma concentrations achievable with quarterly injections in humans, protected all animals against repeated low-dose challenges. In a second experiment, macaques were given GSK744 LA 1 week before virus administration and challenged repeatedly until infection occurred. Protection decreased over time and correlated with the plasma drug levels. With a quarterly dosing schedule in humans, our results suggest that GSK744 LA could potentially decrease adherence problems associated with daily preexposure prophylaxis (PrEP).
Medical subject headings
- HIV Infections
- HIV Integrase Inhibitors
- HIV-1
- Pyridones
- Simian Acquired Immunodeficiency Syndrome
- Simian Immunodeficiency Virus